July 6, 2022
CaaMTech Collaborates with the Alexander Shulgin Research Institute to Study Shulgin Compounds
CaaMTech will help carry on Dr. Alexander Shulgin’s legacy by developing ASRI’s novel compounds
July 6, 2022
CaaMTech will help carry on Dr. Alexander Shulgin’s legacy by developing ASRI’s novel compounds
June 15, 2022
O’Shaughnessy brings decades of experience in intellectual property strategy, collaborations, and development within the life sciences and pharmaceutical industries
June 2, 2022
A new paper published by The Leibniz Institute for Natural Product Research in collaboration with CaaMTech reveals the complex chemistry of magic mushrooms
May 9, 2022
CaaMTech collaborates with UMass Dartmouth to solve crystal structure of overlooked baeocystin
March 15, 2022
CaaMTech scientists have solved the crystal structure of freebase serotonin for the first time
November 16, 2021
Scientists will assess the potential of psychedelic compounds for treating addiction
September 15, 2021
Serotonin is a tryptamine-based human neurotransmitter responsible for a variety of complex biological functions
September 8, 2021
CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing …
May 3, 2021
Dr. Andrew Chadeayne will speak about filling the unmet need for pure, well-characterized tryptamines
April 13, 2021
5-MeO-DPT is a structural analog of 5-MeO-DMT, the “God molecule”